[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@DrSGraff](/creator/twitter/DrSGraff)
"Has there ever been a more true quote Im chronically excitedbut what Im acutely excited about @DrChoueiri outlines whats to come at #ESMO25 and highlights what so many of us are also chronically and acutely excited about @myESMO @OncoAlert"  
[X Link](https://x.com/DrSGraff/status/1979131810710692256) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T10:26Z 21.1K followers, 6762 engagements


"MonarchE adj Abemaciclib shows improved overall survival w/small absolute benefit XXX% relative benefit XXXX% at XX mos Hot take: Incremental improvement is not flashy & exciting like big curve separation but less metastatic disease & more life is good #ESMO25 @OncoAlert"  
[X Link](https://x.com/DrSGraff/status/1979173899423096863) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T13:13Z 21.1K followers, 1484 engagements


"VIKTORIA-1 w PI3K/AKT/mTOR (PAM) pathway Inhibitor gedatolisib + fulvestrant +/- palbo improves PFS in WT as triplet & doublet w/different AEsstomatitis hyperglycemia But it is IV. Weekly. With inavo capi alpeli + many 2L oralswhere do we need geda #ESMO25 @OncoAlert"  
[X Link](https://x.com/DrSGraff/status/1979491524007121283) [@DrSGraff](/creator/x/DrSGraff) 2025-10-18T10:15Z 21.1K followers, 10.7K engagements


"DB05 T-DXd vs TDM1 in pts w/HER2+ RCB after neoadj. cT2N0 excded concurrent ☢ ok CT high res Q12 wks after baseline XXX% in IDFS (HR 0.47) Immature OS DRFS brain met free survival but favorable trend ❓W/shifting data for oral combos is duration & AEs acceptable #ESMO25"  
[X Link](https://x.com/DrSGraff/status/1979568268055855571) [@DrSGraff](/creator/x/DrSGraff) 2025-10-18T15:20Z 21.1K followers, 1366 engagements


"OptiTROP-Breast02 using Sac-TMT (a Trop2 Topo-I ADC) improves PFS HR XXXX as compared to chemotherapy #ESMO25"  
[X Link](https://x.com/DrSGraff/status/1979476863052329352) [@DrSGraff](/creator/x/DrSGraff) 2025-10-18T09:17Z 21.1K followers, 1758 engagements


"TROPION-Breast02 TROPION-Breast02 improves OS and PFS over chemotherapy in 1L MTNBC not eligible for ICI. OS HR XXXX XXXX mos mOS PFS HR XXXX XXXX mos mPFS #ESMO25 introduces a new standard of care pending regulatory approval @OncoAlert"  
[X Link](https://x.com/DrSGraff/status/1979819618819780664) [@DrSGraff](/creator/x/DrSGraff) 2025-10-19T07:59Z 21.1K followers, 1063 engagements


"Its a great day to take a survey #Oncology ONC Oncology Drug Approvals Survey"  
[X Link](https://x.com/DrSGraff/status/1976797400606834797) [@DrSGraff](/creator/x/DrSGraff) 2025-10-10T23:50Z 21.1K followers, XXX engagements


"Dr. @FAndreMD kicks off #ESMO25 - the XX Year Celebration - at Opening Session with his presidential address. @OncoAlert @myESMO"  
[X Link](https://x.com/DrSGraff/status/1979127119469842870) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T10:07Z 21.1K followers, 1115 engagements


"#ESMO25 by the numbers 📝2926 abstracts 📄40 publications 👥 35676 participants @myESMO @OncoAlert"  
[X Link](https://x.com/DrSGraff/status/1979132963938824306) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T10:30Z 21.1K followers, 1780 engagements


"The 🔑 take away at this time of #RIBOLARIS is XX% of patients will shift from high risk to low risk with XX weeks of neoadj letrozole + ribo; will need to understand long term outcome on clinical outcomes like distant disease free survival for example #ESMO25"  
[X Link](https://x.com/DrSGraff/status/1979161770804617461) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T12:25Z 21.1K followers, 1120 engagements


"Long-term follow-up of #POSITIVE trial shows continued safety 71-month median follow-up supporting this model for patients desiring the opportunity to pursue pregnancy after breast cancer. #ESMO25 @OncoAlert"  
[X Link](https://x.com/DrSGraff/status/1979163441102233727) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T12:31Z 21.1K followers, 1497 engagements


"NATALEE Adj Ribo shows sustained improvement in IDFS. Hot take (the dreaded cross trial comparison): NATALEE is a lower risk population so that long slow follow-up is critical with XX% of HR+ recurrences happening X years and that OS trend is promising. #ESMO24 @OncoAlert"  
[X Link](https://x.com/DrSGraff/status/1979175936332316869) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T13:21Z 21.1K followers, 6553 engagements


"Yay @hoperugo 🥂 #EdBook #ASCO26"  
[X Link](https://x.com/DrSGraff/status/1979196623180759366) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T14:43Z 21.1K followers, XXX engagements


"Signs you may be jet lagged You are not sure if you are attending #ESMO24 or #ESMO25 🤦🏼♀"  
[X Link](https://x.com/DrSGraff/status/1979238751151767660) [@DrSGraff](/creator/x/DrSGraff) 2025-10-17T17:31Z 21.1K followers, 2026 engagements


"Although giredestrant + everolimus showed improved PFS in both mutESR1 and ITT (wt and mutESR1) an exploratory analysis suggests that the mutESR1 population is driving the benefit in the ITT group with no difference in PFS for the wt subgroup analysis. #ESMO25 @OncoAlert"  
[X Link](https://x.com/DrSGraff/status/1979465058502451482) [@DrSGraff](/creator/x/DrSGraff) 2025-10-18T08:30Z 21.1K followers, 5111 engagements


"DB11 NeoAdj TDxdx4 THPx4 for HER2+ BC pCR XXXX% (🔺11.2% vs DD AC THP); PCR HR+ XXXX% HRneg XXXX% Reasonable safety but incld Q6 wk high-res CT wh/is clinical challenge ❓With consolidative tx (TDXdpalbo tucatinib TDM1) does everyone needs upfront#ESMO25 @OncoAlert"  
[X Link](https://x.com/DrSGraff/status/1979560902295978292) [@DrSGraff](/creator/x/DrSGraff) 2025-10-18T14:51Z 21.1K followers, 1342 engagements


"SHR-A1811 (trastuzumab rezetecan) improved PFS vs pyrotinib + cape in 2L HER2+ MBC mPFS XXXX vs XXX mos (HR 0.22) 12-month PFS XXXX% vs XXXX% #ESMO25"  
[X Link](https://x.com/DrSGraff/status/1979806283613278608) [@DrSGraff](/creator/x/DrSGraff) 2025-10-19T07:06Z 21.1K followers, 3897 engagements


"ASCENT-03 (1L sacitizumab vs chemo) improved mPFS for mTNBC patients not ICI candidateS mPFS XXX vs XXX mos HR XXXX Crossover allowed 🚨Use of prophylactic G-CSF is advised #ESMO25 @OncoAlert"  
[X Link](https://x.com/DrSGraff/status/1979817744624394347) [@DrSGraff](/creator/x/DrSGraff) 2025-10-19T07:51Z 21.1K followers, 2446 engagements


"If you are excited by 1L TNBC TROP2 ADC at @myESMO TROPION-Breast05 is ✨NOW✨ enrolling PDL1 High 1L mTNBC Breast Cancer globally #ESMO25 @MOliveira_MD @curijoey @LoiSher @RebeccaDSing @OncoAlert"  
[X Link](https://x.com/DrSGraff/status/1979821313813590330) [@DrSGraff](/creator/x/DrSGraff) 2025-10-19T08:05Z 21.1K followers, 1125 engagements


"Both vepdegestrant (TACTIVE-N) and giredrestrant (EMPRESS) are neoadj window of opportunity trials to explore biomarkers and demonstrate that these two novel ETs ***DO THE THINGS*** (Okay thats the cliff notes versionbut its X after all) #ESMO25 @OncoAlert"  
[X Link](https://x.com/DrSGraff/status/1979836924669157597) [@DrSGraff](/creator/x/DrSGraff) 2025-10-19T09:08Z 21.1K followers, 1504 engagements